medigraphic.com
ISSN 2221-2434 (Electronic)

2014, Number 4

<< Back Next >>

Finlay 2014; 4 (4)

Renal impairment: drugs, radiocontrast media and renin-angiotensin system

Chipi CJA, Silveira EJA, Naranjo HA, Méndez LD, Hurtado BG

Language: Spanish
References: 57
Page: 271-283
PDF size: 152.26 Kb.


ABSTRACT

Continuous population aging, coupled with increased prevalence of chronic noncommunicable diseases, particularly diabetes mellitus and hypertension as major causes of impaired renal function, has led to the introduction of new and more powerful drugs for the prevention and treatment of these conditions over the years. This entails an updated knowledge of the pharmacokinetics of these drugs to prevent possible toxic effects, which involves a preliminary assessment of the renal function prior to the introduction of any potentially nephrotoxic substance. The ultimate expression of this nephrotoxicity is hospital-acquired or community-acquired acute renal failure caused by a therapeutic error due to drug misuse in elderly patients with multiple risk factors or pre-existing impaired renal function. The aim of this literature review is to provide health professionals with an abridged and updated vision of the pathophysiological mechanisms related to nephrotoxicity and in turn provide the necessary tools for dose adjustment according to the patient’s renal function.


REFERENCES

  1. Heras M, Fernández JM, Guerrero MT, Sánchez R, Muñoz A, Rodríguez AM. Factores predictores de fracaso renal agudo en ancianos con enfermedad renal crónica. Nefrología. 2012 ; 32 (6): 819-23.

  2. Naughton C. Drug-induced nephrotoxicity. Am. Fam Phy. 2008 ; 78 (6): 743-50.

  3. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med. 2008 ; 36 Suppl 4: SS16-23.

  4. Pérez R. Manejo de medicamentos en los enfermos renales. In: Hernando Avendaño L. Nefrología clínica. 2da. ed. Madrid: Panamericana; 2003. p. 760-71.

  5. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th. ed. Philadelphia: ACP Press; 2007.

  6. Bennett WM, Golper TA. Uso de fármacos en la insuficiencia renal. In: Valderrábano L. Insuficiencia renal crónica, diálisis y trasplante renal. 2da. ed. Madrid: Norma; 1997. p. 1327-53.

  7. Olyaei AJ, De Mattos AM, Bennett WM. Prescribing drugs in renal disease. In: Brenner BM. The kidney. 6th. ed. Philadelphia: WB Saunders; 2000. p. 2606-53.

  8. Baumelou A. Insuficiencia renal crónica. EMC - Tratado de Medicina. 2004 ; 87 (1): 1-8.

  9. Perazella M. Toxic nephropathies: core curriculum 2010. Am J Kidney Dis. 2010 ; 55 (2): 399-409.

  10. Morales AI, Arévalo M, Pérez F. Mecanismos implicados en la nefrotoxicidad producida por aminoglucósidos. Nefrología. 2000 ; 20 (5): 1-15.

  11. Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int. 1979 ; 15 (4): 335-45.

  12. Sastrasinh M, Kanauss TC, Weinberg JM, Humes HD. Identification of the aminoglycoside binding site in rat renal brush border membranes. J Pharmacol Exp Ther. 1982 ; 222 (2): 350-8.

  13. Senekjian HO, Knight TF, Weinman EJ. Micropuncture study of the handling of gentamicin by the rat kidney. Kidney Int. 1981 ; 19 (3): 416-23.

  14. Pastoriza E, Bowman RL, Kaloyanides GJ. Renal tubular transport of gentamicin in the rat. Kidney Int. 1979 ; 16 (4): 440-50.

  15. Frommer JP, Senekjian HO, Babino H, Weinman EJ. Intratubular microinjection study of gentamicin transport in the rat. Miner Electrolyte Metab. 1983 ; 9 (2): 108-12.

  16. Leehey DJ, Braun BI, Tholl DA, Chung LS, Gross CA, Roback JA, et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy?. J Am Soc Nephrol. 1993 ; 4 (1): 81-90.

  17. Whiting PH, Brown PA. The relationship between enzymuria and kidney enzyme activities in experimental gentamicin nephrotoxicity. Ren Fail. 1996 ; 18 (6): 899-909.

  18. López de Abechuco IP, Gálvez MA, Rodríguez D, Del Rey JM, Prieto E, Cuchi M, et al. Uso de antiinflamatorios no esteroideos y monitorización de la función renal. Estudio piloto en un centro de salud de Atención Primaria. Nefrología. 2012 ; 32 (6): 777-81.

  19. Vonkeman HE, Van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum. 2010 ; 39 (4): 294-312.

  20. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis. 1996 ; 28 (1 Suppl 1): SS56-62.

  21. Martínez CV, Ponte M, Di Tullio D. Toxicidad renal generada por medicamentos. Salud Cienc. 2011 ; 18 (5): 454.

  22. Stillman MT, Schlesinger PA. Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned?. Arch Interm Med. 1990 ; 150 (2): 268-70.

  23. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984 ; 310 (9): 563-72.

  24. Avellán M. Nefropatías por tóxicos: mecanismos de lesión y manifestaciones clínicas. Revista Clínica de la Escuela de Medicina UCR – HSJD. 2012 ; 2 (1): 1-7.

  25. Balparda JK, Gaviria ME. Nefropatía inducida por medios de contraste radiológico yodados. IATREIA. 2008 ; 21 (2): 1-15.

  26. Bouzas A, Vásquez JM, Calviño R, Peteiro J, Flores X, Marzoa R, et al. Contrast-induced nephropathy and acute renal failure following emergent cardiac catheterization: incidence, risk factors, and prognosis. Rev Esp Cardiol. 2007 ; 60 (10): 1026-34.

  27. Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, et al. Sodium bicarbonate, N-acetylcysteine and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007 ; 154 (3): 539-44.

  28. Lawlor DK, Moist L, DeRose G, Harris KA, Lovell MB, Kribs SW, et al. Prevention of contrast-induced nephropathy in vascular surgery patients. Ann Vasc Surg. 2007 ; 21 (5): 593-7.

  29. Lameire N, Van Biesen W, Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol. 2006 ; 2 (7): 364-77.

  30. Kabalan SN, El-Imad BG, Geara AS. Contrast-induced nephropathy. J Med Liban. 2007 ; 55 (1): 29-38.

  31. Solomon R. Contrast media nephropathy: how to diagnose and how to prevent?. Nephrol Dial Transplant. 2007 ; 22 (7): 1812-5.

  32. Walsh SR, Tang T, Gaunt ME, Boyle HR. Contrast-induced nephropathy. J Endovasc Ther. 2007 ; 14 (1): 92-100.

  33. Detrenis S, Meschi M, Musini G, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005 ; 20 (8): 1542-50.

  34. Arakawa K, Suzuki H, Naitoh M, Matsumoto A, Hayashi K, Matsuda H, et al. Role of adenosine in the renal responses to contrast medium. Kidney Int. 1996 ; 49 (5): 1199-1206.

  35. Oldroyd SD, Fang L, Haylor JL, Yates MS, El Nahas AM, Morcos SK. Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rat kidney. Clin Sci (Lond). 2000 ; 98 (3): 303-11.

  36. Thomsen HS. How to avoid CIN: guidelines from the European Society of Urogenital Radiology. Nephrol Dial Transplant. 2005 ; 20 Suppl 1: S18-22.

  37. Stacul F. Reducing the risk for contrast-induced nephropathy. Cardiovasc Intervent Radiol. 2005 ; 28 Suppl 2: SS12-8.

  38. Pedone C, Corsonello A, Incalzi RA, GIFA Investigators. Estimating renal function in older people: a comparison of three formulas. Age Ageing. 2006 ; 35 (2): 121-6.

  39. Eknoyan G. Chronic kidney disease definition and classification: the quest for refinements. Kidney Int. 2007 ; 72 (10): 1183-5.

  40. Kukla A, Adulla M, Pascual J, Samaniego M, Nanovic L, Becker BN, et al. CKD stage-to-stage progression in native and transplant kidney patients. Nephrol Dial Transplant. 2008 ; 23 (2): 693-700.

  41. Barreto R. Prevention of contrast-induced nephropathy: the rational use of sodium bicarbonate. Nephrol Nurs J. 2007 ; 34 (4): 417-21.

  42. Masuda M, Yamada T, Mine T, Morita T, Yamaki S, Tsukamoto Y, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol. 2007 ; 100 (5): 781-6.

  43. Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B, et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. Am J Roentgenol. 2007 ; 189 (3): 687-92.

  44. Van Praet JT, DeVriesse AS. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens. 2007 ; 16 (4): 336-47.

  45. Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant. 2008 ; 23 (3): 853-9.

  46. Górriz JL, Beltrán S. Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes. Rev Esp Cardiol. 2011 ; 64 (12): 1182-92.

  47. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002 ; 347 (16): 1256-61.

  48. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993 ; 329 (20): 1456-62.

  49. Apperloo AJ, De Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 1997 ; 51 (3): 793-7.

  50. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 ; 327 (10): 685-91.

  51. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction results: of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004 ; 110 (17): 2618-26.

  52. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 (15): 1547-59.

  53. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004 ; 351 (6): 585-92.

  54. Maher JF. Pharmacological considerations for renal failure and dialysis. Replacement of renal functions by dialysis. 3rd. ed. The Netherlands: Kluver Academic Publishers; 1989.

  55. Ortiz Y, García MM, Rosales KK, Figueredo L. Utilización de fármacos en la insuficiencia renal. Rev Cubana Farm. 2007 ; 41 (2): 1-15.

  56. National Kidney Foundation. K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002 ; 39 (2 Suppl 1): SS1-266.

  57. Sande MA, Kapusnik-Uner JE, Mandell GL. Agentes anti-microbianos. Consideraciones




2020     |     www.medigraphic.com